PDP Pediapharm

Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE:PDP) advises
there have been changes to its Board of Directors. Mr. Angelo Botter has
resigned as a director of the Company to pursue other matters. The Corporation's
board of directors would like to thank Mr. Botter for his invaluable
contribution to the success of Pediapharm since it was founded and wish him well
in his future endeavors.


The Corporation is pleased to announce that Michael P. Mueller has agreed to
join the Board of Directors. Mr. Mueller is currently the Chairman of Annidis
Corporation and a director of several companies including PSP Investments, the
Canadian Tire Bank, Magor Communications Corp. and Emily's House. From 2003 to
2005, he was the President and CEO of MDS Capital Corporation. Mr. Mueller
previously held a series of senior executive positions at TD Bank, including
Vice Chairman and Global Head of Investment and Corporate Banking. He is a
former member of the Board of Directors of the Scarborough Hospital (past
Chair), the Scarborough Hospital Foundation, AIM Therapeutics Inc., Biovest
Corp. 1, Budco, TM BioScience, MDS Capital Corporation and Canadian Medical
Discoveries Funds I and II. Mr. Mueller holds a Bachelor of Science from the
University of Western Ontario and an MBA from York University.


"We are very much looking forward to Mr. Mueller's contributions as he brings
tremendous experience not only in the health care sector but also in the small
cap investment space. It was also important for us to bring expertise and Board
presence across Canada and Mike's appointment fits perfectly with this
objective" said Sylvain Chretien, President and CEO of Pediapharm. 


"Pediapharm will greatly benefit from Mr. Mueller's extensive background and
experience. Mike definitely brings a complementary skill set to the existing
Board and management team and we are looking forward to his contributions,"
commented Mr. Pierre Lapalme, Chairman of Pediapharm.


About Pedipharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and
Camphor.


Neither the TSX Venture Exchange nor its Regulation Service Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pediapharm Inc.
Sylvain Chretien
President and Chief Executive Officer
+1-514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com


Roland Boivin
Chief Financial Officer
+1-514-762-2626 ext. 202
roland.boivin@pedia-pharm.com


Relations Publiques Paradox Public Relations Inc.
Carl Desjardins
+1-514-341-0408
carldesjardins@paradox-pr.ca

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024